Kennedy’s decision to replace ACIP wholesale and the comments he has made about deviating from standard vaccine policymaking ...

Robert F. Kennedy Jr. has repeated that not enough childhood vaccines have been tested in clinical trials against a placebo.

Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since early June, the stock has broken through its 50-day simple moving ...

Jefferies analyst Akash Tewari remains bullish on Merck, maintaining a Buy rating and a $138 price target. The firm’s ...